Page 58 - Haematologica Vol. 109 - July 2024

REVIEW ARTICLE - CXCL8 in primary myelofibrosis
G. Vermeersch et al.
80. Boveri E, Passamonti F, Rumi E, et al. Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations. Br J Haematol. 2008;140(2):162-168.
81. Wróbel T, Mazur G, Surowiak P, Wolowiec D, Jelen M, Kuliczkowsky K. Increased expression of vascular endothelial growth factor (VEGF) in bone marrow of patients with myeloproliferative disorders (MPD). Pathol Oncol Res. 2003;9(3):170-173.
82. Schraufstatter IU, Chung J, Burger M. IL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and Rac signaling pathways. Am J Physiol Lung Cell Mol Physiol. 2001;280(6):L1094-L1103.
83. Strieter RM, Polverini PJ, Kunkel SL, et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem. 1995;270(45):27348-27357.
84. Metzemaekers M, Gouwy M, Proost P. Neutrophil chemoattractant receptors in health and disease: double-edged swords. Cell Mol Immunol. 2020;17(5):433-450.
85. Schmidt S, Daniliants D, Hiller E, Gunsilius E, Wolf D, Feistritzer C. Increased levels of NETosis in myeloproliferative neoplasms are not linked to thrombotic events. Blood Adv. 2021;5(18):3515-3527.
86. Marin Oyarzún CP, Carestia A, Lev PR, et al. Neutrophil extracellular trap formation and circulating nucleosomes in patients with chronic myeloproliferative neoplasms. Sci Rep. 2016;6:38738.
87. Wolach O, Sellar RS, Martinod K, et al. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med. 2018;10(436):eaan8292.
88. Hauser CJ, Fekete Z, Goodman ER, Kleinstein E, Livingston DH, Deitch EA. CXCR2 stimulation primes CXCR1 [Ca2+]i responses to IL-8 in human neutrophils. Shock. 1999;12(6):428-437.
89. Sabroe I, Jones EC, Whyte MKB, Dower SK. Regulation of human neutrophil chemokine receptor expression and function by activation of Toll-like receptors 2 and 4. Immunology. 2005;115(1):90-98.
90. Martin C, Burdon PCE, Bridger G, Gutierrez-Ramos JC, Williams TJ, Rankin SM. Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence. Immunity. 2003;19(4):583-593.
91. Eash KJ, Greenbaum AM, Gopalan PK, Link DC. CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from murine bone marrow. J Clin Invest. 2010;120(7):2423-2431.
92. Kim HK, De La Luz Sierra M, Williams CK, Gulino AV, Tosato G. G-CSF down-regulation of CXCR4 expression identified as a
mechanism for mobilization of myeloid cells. Blood.
2006;108(3):812-820.
93. Liu Q, Li A, Tian Y, et al. The CXCL8-CXCR1/2 pathways in cancer.
Cytokine Growth Factor Rev. 2016;31:61-71.
94. Schinke C, Giricz O, Li W, et al. IL8-CXCR2 pathway inhibition as
a therapeutic strategy against MDS and AML stem cells. Blood.
2015;125(20):3144-3152.
95. Fuhler GM, Knol GJ, Drayer AL, Vellenga E. Impaired
interleukin-8- and GROalpha-induced phosphorylation of extracellular signal-regulated kinase result in decreased migration of neutrophils from patients with myelodysplasia. J Leukoc Biol. 2005;77(2):257-266.
96. Schuster M, Moeller M, Bornemann L, et al. Surveillance of myelodysplastic syndrome via migration analyses of blood neutrophils: a potential prognostic tool. J Immunol. 2018;201(12):3546-3557.
97. Verachi P, Gobbo F, Martelli F, et al. The CXCR1/CXCR2 inhibitor reparixin alters the development of myelofibrosis in the Gata1low mice. Front Oncol. 2022;12:853484.
98. National Cancer Institute (NCI). A phase II study of reparixin in patients with myelofibrosis Myeloproliferative Neoplasms Research Consortium [MPN-RC 120]. https://www.clinicaltrials. gov/study/NCT05835466?cond=NCT05835466&rank=1 Accessed January 26, 2024.
99. Sitaru S, Budke A, Bertini R, Sperandio M. Therapeutic inhibition of CXCR1/2: where do we stand? Intern Emerg Med. 2023;18(6):1647-1664.
100. Keir HR, Richardson H, Fillmore C, et al. CXCL-8-dependent and -independent neutrophil activation in COPD: experiences from a pilot study of the CXCR2 antagonist danirixin. ERJ Open Res. 2020;6(4):00583-02020.
101. Sallman DA, DeZern AE, Gayle AA, et al. Phase 1 results of the first-in-class CXCR1/2 inhibitor SX-682 in patients with hypomethylating agent failure myelodysplastic syndromes. Blood. 2022;140(Suppl 1):2070-2072.
102. Schalper KA, Carleton M, Zhou M, et al. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nat Med. 2020;26(5):688-692.
103. Ramachandra N, Gupta M, Schwartz L, et al. Role of IL8 in myeloid malignancies. Leuk Lymphoma. 2023;64(11):1742-1751.
104. National Cancer Institute (NCI). A phase I/II trial of BMS-986253 in myelodysplastic syndromes. clinicaltrials.gov; 2022. https:// clinicaltrials.gov/study/NCT05148234. Accessed December 22, 2023.
105. Tremblay D, Mesa R. Novel treatments for myelofibrosis: beyond JAK inhibitors. Int J Hematol. 2022;115(5):645-658.
Haematologica | 109 July 2024
2072